Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
pharmaphorum2d
EMA abandons X in favour of rival Bluesky
The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
Pharm Exec3d
EMA Takes Break From X, Joins Bluesky
The government agency says X no longer suits its communication needs.
devdiscourse4d
EMA Shifts Digital Platform from X to Bluesky Amid Content Concerns
The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back ...
EU medicines agency quits X, moves to Bluesky
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
LIVE news updates: Coal India's Q3 net profit falls 17% to Rs 8,506 crore, beats estimate
The stolen cash and gold ornaments worth Rs four crore have been recovered, and four people have been arrested in connection ...